Supplementary Materials

CIRP contributes to multiple organ damage in acute pancreatitis by increasing endothelial permeability

Wuming Liu^{1,2}, Derek H. Wu³, Tao Wang^{1,2}, Mengzhou Wang^{1,2}, Yujia Xu⁴, Yifan Ren^{1,5}, Yi Lyu^{1,2}, Rongqian Wu¹

¹ National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, Shaanxi Provincial Center for Regenerative Medicine and Surgical Engineering, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Supplementary Table 1: Basic clinical data of the patients.

| Total (N) 119 Age (years) 52 ± 12.5 Gender (male/female) 71/48 BMI (kg/m²) 22.4. ± 1.6 Severity of illness *** | Variables | (%) or Mean ± SD |
|--|------------------------------------|------------------|
| Gender (male/female) 71/48 BMI (kg/m²) 22.4. ± 1.6 Severity of illness 55 (46.2%) Mild acute pancreatitis 36 (30.3%) Moderate severe acute pancreatitis 28 (23.5%) Epidemic factor 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Total (N) | 119 |
| BMI (kg/m²) 22.4. ± 1.6 Severity of illness 55 (46.2%) Mild acute pancreatitis 36 (30.3%) Severe acute pancreatitis 28 (23.5%) Epidemic factor biliary system diseases 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Age (years) | 52 ± 12.5 |
| Severity of illness Mild acute pancreatitis 55 (46.2%) Moderate severe acute pancreatitis 36 (30.3%) Severe acute pancreatitis 28 (23.5%) Epidemic factor biliary system diseases 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment Supportive treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Gender (male/female) | 71/48 |
| Mild acute pancreatitis 55 (46.2%) Moderate severe acute pancreatitis 36 (30.3%) Severe acute pancreatitis 28 (23.5%) Epidemic factor 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | BMI (kg/m^2) | $22.4. \pm 1.6$ |
| Moderate severe acute pancreatitis Severe acute pancreatitis 28 (23.5%) Epidemic factor biliary system diseases 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment Supportive treatment Supportive treatment Percutaneous Drainage 12 (10.1%) | Severity of illness | |
| Severe acute pancreatitis Epidemic factor biliary system diseases 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol Alcohol Others 39 (32.8%) Treatment Supportive treatment Percutaneous Drainage 12 (10.1%) | Mild acute pancreatitis | 55 (46.2%) |
| Epidemic factor biliary system diseases full 42.0% Hyperlipidemia Alcohol Others Treatment Supportive treatment Percutaneous Drainage 50 (42.0%) (| Moderate severe acute pancreatitis | 36 (30.3%) |
| biliary system diseases 50 (42.0%) Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment Supportive treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Severe acute pancreatitis | 28 (23.5%) |
| Hyperlipidemia 26 (21.8%) Alcohol 4 (3.4%) Others 39 (32.8%) Treatment Supportive treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Epidemic factor | |
| Alcohol 4 (3.4%) Others 39 (32.8%) Treatment Supportive treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | biliary system diseases | 50 (42.0%) |
| Others 39 (32.8%) Treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Hyperlipidemia | 26 (21.8%) |
| Treatment Supportive treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Alcohol | 4 (3.4%) |
| Supportive treatment 87 (73.1%) Percutaneous Drainage 12 (10.1%) | Others | 39 (32.8%) |
| Percutaneous Drainage 12 (10.1%) | Treatment | |
| | Supportive treatment | 87 (73.1%) |
| Surgery 20 (16.8%) | Percutaneous Drainage | 12 (10.1%) |
| | Surgery | 20 (16.8%) |

² Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China


³ Macaulay Honors College, CUNY Brooklyn College, Brooklyn, NY 11210, USA

⁴ Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

⁵ Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

| APACHE II scores | 6.33 ± 6.1 |
|-------------------------------|-------------------|
| SOFA scores | 2.62 ± 4 |
| Complication (with/with out) | 44/75 |
| Organ failure (with/with out) | 25/94 |
| PCT (ng/ml) | 2.9 ± 5.8 |
| CRP (mg/L) | 139.5 ± 153 |
| Serum lipase (U/L) | 1793.5 ± 1831 |
| Serum amylase (U/L) | 790 ± 1024 |
| Serum glucose (mmol/L) | 8.7 ± 6.6 |
| HbA1c (%) | 5.3 ± 3.1 |
| WBC $(\times 10^9/L)$ | 11.7 ± 5.5 |
| Serum Cr (µmol/L) | 78.5 ± 102 |
| Serum BUN (mmol/L) | 6.5 ± 8.7 |
| Hct (%) | 40.5 ± 9.7 |
| Serum Calcium (mmol/L) | 1.95 ± 0.4 |


APACHE II: Acute Physiology and Chronic Health Evaluation; SOFA: sepsis-related organ failure assessment.



Supplementary Figure 1. Serum CIRP levels are decreased in AP patients.

- **A.** Serum CIRP levels in AP patients and healthy controls.
- **B.** Serum CIRP levels in different degree AP patients. (MAP: Mild acute pancreatitis.; MSAP: Moderately severe acute pancreatitis; SAP: Severe acute pancreatitis.)
- C. Serum CIRP levels in AP patients with or without organ failure.
- **D.** Serum CIRP levels in AP patients with or without complication.
- E. Correlation analysis of serum CIRP levels and SOFA scores.
- F. Correlation analysis of serum CIRP levels and APACHE-II scores.


Data are expressed as mean \pm standard deviations. *p < 0.05.



Supplementary Figure 2. The qPCR results of the knockout efficiency of CIRP KO mice.

The CIRP mRNA levels in various organs of CIRP KO mice.

n=6/group; *p < 0.05 compared with the Wild Type mice. Data are expressed as mean \pm standard deviations.



Supplementary Figure 3. The analysis of inflammatory mediators for serum IL-6, TNF-α and IL-1β.

L-Arginine-AP was induced by two hourly intraperitoneal injections of 4.0 g/kg L-arginine in WT or CIRP KO mice.

For C23 treatment group, at 2h after the last L-arginine injection, C23(8mg/kg) was administered via intraperitoneal injection. The animals were sacrificed at 72 h post-first L-arginine injection.

- A. Serum IL-6 levels.
- B. Serum TNF- α levels.
- C. Serum IL-1β levels.

n = 6/group; *p < 0.05 compared with the sham mice. *p < 0.05 compared with the WT-AP mice. Data are expressed as

mean \pm standard deviations.

Supplementary Figure 4. Uncropped and unedited blot images.




Fig 1A uncropped gel. CIRP levels are upregulated in multiple organs in the experimental AP model.

Entire membranes of the representative Western blot of ACTIN and CIRP, as shown in Fig 1A are provided. Of note, complete membranes were cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 2D uncropped gel. CIRP deficiency mitigates pancreatic tissue damage and edema in the AP mouse model. Entire membranes of the representative Western

blot of ACTIN and RIP-3, as shown in Fig 2D are provided. Of note, complete membranes were cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 3D uncropped gel. CIRP deficiency mitigates intestinal tissue damage and edema in the AP mouse model. Entire membranes of the representative Western blot of ACTIN and RIP-3, as shown in Fig 3D are provided. Of note, complete

membranes were cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 4D uncropped gel. CIRP deficiency mitigates pulmonary tissue damage and edema in the AP mouse model. Entire membranes of the representative Western blot of ACTIN and RIP-3, as shown in Fig 4D are provided. Of note, complete membranes

were cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 5D uncropped gel. CIRP deficiency mitigates hepatic tissue damage and

edema in the AP mouse model.

Entire membranes of the representative Western blot of ACTIN and RIP-3, as shown in Fig 5D are provided. Of note, complete membranes were cut horizontally

after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 6D uncropped gel. C23 mitigates pancreatic tissue damage and edema in the

AP mouse model. Entire membranes of the representative Western blot of ACTIN

and RIP-3, as shown in Fig 6D are provided. Of note, complete membranes were

cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 7D uncropped gel. C23 mitigates intestinal tissue damage and edema in the AP mouse model. Entire membranes of the representative Western blot of ACTIN and RIP-3, as shown in Fig 7D are provided. Of note, complete membranes were

cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 8D uncropped gel. C23 mitigates pulmonary tissue damage and edema in the AP mouse model. Entire membranes of the representative Western blot of ACTIN and RIP-3, as shown in Fig 8D are provided. Of note, complete membranes

were cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 9D uncropped gel. C23 mitigates hepatic tissue damage and edema in the AP mouse model. Entire membranes of the representative Western blot of ACTIN and RIP-3, as shown in Fig 9D are provided. Of note, complete membranes were

cut horizontally after protein transfer to allow for simultaneous incubation with different antibodies.




Fig 10C uncropped gel. CIRP can damage the endothelial cell barrier directly. Entire membranes of the representative Western blot of ACTIN and p-Src (Y416), as shown in Fig 10C are provided. Of note, complete membranes were cut

horizontally after protein transfer to allow for simultaneous incubation with different antibodies.